» Articles » PMID: 26711265

The N Terminus of the Retinoblastoma Protein Inhibits DNA Replication Via a Bipartite Mechanism Disrupted in Partially Penetrant Retinoblastomas

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2015 Dec 30
PMID 26711265
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The N-terminal domain of the retinoblastoma (Rb) tumor suppressor protein (RbN) harbors in-frame exon deletions in partially penetrant hereditary retinoblastomas and is known to impair cell growth and tumorigenesis. However, how such RbN deletions contribute to Rb tumor- and growth-suppressive functions is unknown. Here we establish that RbN directly inhibits DNA replication initiation and elongation using a bipartite mechanism involving N-terminal exons lost in cancer. Specifically, Rb exon 7 is necessary and sufficient to target and inhibit the replicative CMG helicase, resulting in the accumulation of inactive CMGs on chromatin. An independent N-terminal loop domain, which forms a projection, specifically blocks DNA polymerase α (Pol-α) and Ctf4 recruitment without affecting DNA polymerases ε and δ or the CMG helicase. Individual disruption of exon 7 or the projection in RbN or Rb, as occurs in inherited cancers, partially impairs the ability of Rb/RbN to inhibit DNA replication and block G1-to-S cell cycle transit. However, their combined loss abolishes these functions of Rb. Thus, Rb growth-suppressive functions include its ability to block replicative complexes via bipartite, independent, and additive N-terminal domains. The partial loss of replication, CMG, or Pol-α control provides a potential molecular explanation for how N-terminal Rb loss-of-function deletions contribute to the etiology of partially penetrant retinoblastomas.

Citing Articles

The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations.

Xiang S, Reed D, Alexandrow M Oncogene. 2022; 42(7):473-490.

PMID: 36522488 PMC: 9948756. DOI: 10.1038/s41388-022-02572-8.


Peptide-tiling screens of cancer drivers reveal oncogenic protein domains and associated peptide inhibitors.

Ford K, Panwala R, Chen D, Portell A, Palmer N, Mali P Cell Syst. 2021; 12(7):716-732.e7.

PMID: 34051140 PMC: 8298269. DOI: 10.1016/j.cels.2021.05.002.


TGFβ1 Cell Cycle Arrest Is Mediated by Inhibition of MCM Assembly in Rb-Deficient Conditions.

Nepon-Sixt B, Alexandrow M Mol Cancer Res. 2018; 17(1):277-288.

PMID: 30257992 PMC: 6318023. DOI: 10.1158/1541-7786.MCR-18-0558.


Parent-of-origin effect of hypomorphic pathogenic variants and somatic mosaicism impact on phenotypic expression of retinoblastoma.

Imperatore V, Pinto A, Gelli E, Trevisson E, Morbidoni V, Frullanti E Eur J Hum Genet. 2018; 26(7):1026-1037.

PMID: 29662154 PMC: 6018773. DOI: 10.1038/s41431-017-0054-6.


The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.

Seo Y, Kang Y Front Mol Biosci. 2018; 5:26.

PMID: 29651420 PMC: 5885281. DOI: 10.3389/fmolb.2018.00026.


References
1.
Edwards M, Tutter A, Cvetic C, Gilbert C, Prokhorova T, Walter J . MCM2-7 complexes bind chromatin in a distributed pattern surrounding the origin recognition complex in Xenopus egg extracts. J Biol Chem. 2002; 277(36):33049-57. DOI: 10.1074/jbc.M204438200. View

2.
Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y . Retinoblastoma gene mutations in primary human prostate cancer. Prostate. 1995; 27(6):314-20. DOI: 10.1002/pros.2990270604. View

3.
Lee J, Kumagai A, Dunphy W . Claspin, a Chk1-regulatory protein, monitors DNA replication on chromatin independently of RPA, ATR, and Rad17. Mol Cell. 2003; 11(2):329-40. DOI: 10.1016/s1097-2765(03)00045-5. View

4.
Goodrich D . How the other half lives, the amino-terminal domain of the retinoblastoma tumor suppressor protein. J Cell Physiol. 2003; 197(2):169-80. DOI: 10.1002/jcp.10358. View

5.
Avni D, Yang H, Martelli F, Hofmann F, ElShamy W, Ganesan S . Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol Cell. 2003; 12(3):735-46. DOI: 10.1016/s1097-2765(03)00355-1. View